

February 13, 2018

PositiveID's Thermomedics Delivers First 500 Caregiver Bluetooth Thermometers to Global Healthcare Company

New version of Caregiver is the first FDA cleared non-contact, infrared thermometer intended for professional use that utilizes Bluetooth technology to connect wirelessly to patient monitoring stations and electronic health records systems

DELRAY BEACH, Fla., Feb. 13, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that its Thermomedics subsidiary has delivered its first 500 Bluetooth®-enabled Caregiver® thermometers to a large global healthcare customer. Caregiver with Bluetooth was launched in January 2018.

The new, advanced version of Caregiver is the first FDA cleared non-contact, infrared thermometer intended for professional use that utilizes Bluetooth technology to connect wirelessly to patient monitoring stations and electronic health records systems to transmit temperature readings automatically into a patient's record to increase efficiency and accuracy.

Caregiver delivers an oral-equivalent temperature in one to two seconds directly from the forehead, without contact, for adults, children, and infants. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as \$0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of \$250 or more per year per device in probe cover supplies alone.

"The use of wireless technology in hospitals is becoming universal, and we believe our new version of Caregiver with Bluetooth can help automate electronic health records keeping for improved accuracy and efficiency," stated Gary O'Hara, Chief Technology Officer of Thermomedics. "We are optimistic that as healthcare professionals experience the benefits of this new version of Caregiver, more customers will follow suit and we will see an increase in our market share."

PositiveID believes its next generation Bluetooth-enabled Caregiver thermometer holds the potential to boost adoption of the Caregiver line to take advantage of the growing use of infrared thermometry, which is the fastest growing segment of the \$1 billion global temperature monitoring device market according to Global Industry Analysts, Inc.

Caregiver is marketed by Thermomedics, Inc., a wholly owned subsidiary of PositiveID.

About PositiveID Corporation

PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit <http://www.psidcorp.com>, or connect with PositiveID on [Twitter](#), [Facebook](#) or [LinkedIn](#).

Statements about PositiveID's future expectations, including the likelihood that that Caregiver can offer savings of \$250 or more per year per device in probe cover supplies alone; the likelihood that the new version of Caregiver with Bluetooth can help automate electronic health records keeping for improved accuracy and efficiency; the likelihood that as healthcare professionals experience the benefits of this new version of Caregiver, more customers will follow suit and the Company will see an increase in its market share; the likelihood that the next generation Bluetooth-enabled Caregiver thermometer holds the potential to boost adoption of the Caregiver line to take advantage of the growing use of infrared thermometry, which is the fastest growing segment of the \$1 billion global temperature monitoring device market; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to attract new customers and retain existing customers; the Company's ability to target the professional healthcare market; the Company's ability to raise capital; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 31, 2017, and 10-Qs filed on November 13, 2017, August 14, 2017, and May 15, 2017, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

PositiveID Corporation
Allison Tomek
(561) 805-8044
atomek@psidcorp.com



Source: PositiveID Corporation